Document is current
Any future updates will be listed below
-
Authors
Mock, Andreas http://orcid.org/0000-0002-3332-9166
Teleanu, Maria-Veronica
Kreutzfeldt, Simon
Heilig, Christoph E. http://orcid.org/0000-0001-8869-1421
Hüllein, Jennifer
Möhrmann, Lino http://orcid.org/0000-0003-4650-6827
Jahn, Arne
Hanf, Dorothea
Kerle, Irina A.
Singh, Hans Martin http://orcid.org/0000-0001-7214-9339
Hutter, Barbara
Uhrig, Sebastian
Fröhlich, Martina
Neumann, Olaf http://orcid.org/0000-0003-2684-9187
Hartig, Andreas
Brückmann, Sascha
Hirsch, Steffen http://orcid.org/0000-0002-4920-0930
Grund, Kerstin
Dikow, Nicola
Lipka, Daniel B. http://orcid.org/0000-0001-5081-7869
Renner, Marcus
Bhatti, Irfan Ahmed
Apostolidis, Leonidas
Schlenk, Richard F.
Schaaf, Christian P.
Stenzinger, Albrecht http://orcid.org/0000-0003-1001-103X
Schröck, Evelin http://orcid.org/0000-0002-3377-1704
Hübschmann, Daniel http://orcid.org/0000-0002-6041-7049
Heining, Christoph
Horak, Peter http://orcid.org/0000-0003-4536-9306
Glimm, Hanno
Fröhling, Stefan http://orcid.org/0000-0001-7907-4595
- License Information
-
More Information
Article History
Received: 2 April 2023
Accepted: 26 September 2023
First Online: 26 October 2023
Competing interests
: C.E.H.: Consulting or advisory board membership: Boehringer Ingelheim; honoraria: Novartis, Roche; research funding: Boehringer Ingelheim. S.F.: Consulting or advisory board membership: Bayer, Illumina, Roche; honoraria: Amgen, Eli Lilly, PharmaMar, Roche; research funding: AstraZeneca, Pfizer, PharmaMar, Roche; travel or accommodation expenses: Amgen, Eli Lilly, Illumina, PharmaMar, Roche.
